主要文件

查看所有文档

B8299

N-Butyldeoxynojirimycin

Name: N-Butyldeoxynojirimycin
Brand: SIGMA

film (dried in situ), ≥98% (TLC)

别名:

Miglustat, NB-DNJ

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₀H₂₁NO₄

化学文摘社编号:

72599-27-0

分子量:

219.28

UNSPSC Code:

12352200

PubChem Substance ID:

24892070

NACRES:

NA.32

MDL number:

MFCD00272581

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

N-Butyldeoxynojirimycin, film (dried in situ)

assay

≥98% (TLC)

Quality Level

200

form

film (dried in situ)

solubility

water: 9.80-10.20 mg/mL, clear, colorless

storage temp.

2-8°C

SMILES string

CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO

InChI

1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1

InChI key

UQRORFVVSGFNRO-UTINFBMNSA-N

Gene Information

human ... UGCG(7357)

说明

General description

N-Butyldeoxynojirimycin is an alkylated product of imino sugar deoxynojirimycin.

Application

N-Butyldeoxynojirimycin has been used:

in the inhibition of glycolipid synthesis in neuroblastoma cells
in the inhibition the ceramide-specific glycosyltransferase in hepatocytes
in the inhibition of β-glucosidase (GBA2) using fluorescence- activity assay in human embryonic kidney (HEK293) cells.

Biochem/physiol Actions

N-Butyldeoxynojirimycin is an inhibitor of glucosyltransferase and α-glucosidases. N-Butyldeoxynojirimycin, also known as misglustat, reduces glycolipid levels by substrate reduction therapy (SRT) and is effectively used for the treatment of glycosphingolipid lysosomal storage disorder, Gaucher disease.

α-glucosidase Inhibitor

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.

Platt FM et al.

The Journal of Biological Chemistry, 269(11), 8362-8365 (1994)

Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution.

Maciej Machaczka et al.

Upsala journal of medical sciences, 117(1), 28-34 (2012-01-18)

Gaucher disease (GD) is an infrequent progressive multisystem lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme, glucocerebrosidase. A retrospective, single-center analysis of the clinical experience concerning the use of miglustat (N-butyldeoxynojirimycin), an oral inhibitor of glucosylceramide

Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment.

Aizeddin Mhanni et al.

Diagnostics (Basel, Switzerland), 10(2) (2020-01-30)

Intraocular lesions have been infrequently reported in patients with Gaucher disease type 3 (GD3). We previously reported siblings with GD3 who responded well to the combination of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Here we report progressive

查看所有相关文献

全球贸易项目编号

货号	GTIN
B8299-1MG	04061826740996
B8299-5MG	04061833627846